Benjamin Halladay, Chief Financial Officer at Esperion Therapeutics, Inc. (ESPR), sold 7,046 shares at $2.81 ($20K) on 2025-09-17, disclosed to the SEC on 2025-09-18.
Open-market sale of $20k ESPR by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| ESPR | SELL | 2025-12-18 | $27K | — | Filing → |
| ESPR | SELL | 2025-07-18 | $12 | — | Filing → |
| ESPR | SELL | 2025-06-18 | $8K | — | Filing → |